Integrating cryptococcal antigen screening and pre-emptive treatment into routine HIV care

Journal of Acquired Immune Deficiency Syndromes

Volumn 59, Issue 5, 2012, Pages

  Rajasingham, Radha ^a   Meya, David B ^b   Boulware, David R ^c  

^a MAKERERE UNIVERSITY   (Uganda)

^b UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

^c MAKERERE UNIVERSITY COLLEGE OF HEALTH SCIENCES   (Uganda)

Author keywords

Cost effectiveness; Cryptococcal meningitis DI; Cryptococcosis; HIV; Point of care systems; Review

Indexed keywords

BACTERIAL ANTIGEN; CRYPTOCOCCUS ANTIGEN; FLUCONAZOLE; RIFAMYCIN; UNCLASSIFIED DRUG;

ANTIGEN DETECTION; ANTIMICROBIAL THERAPY; ARTICLE; CD4 LYMPHOCYTE COUNT; COST EFFECTIVENESS ANALYSIS; CRYPTOCOCCAL MENINGITIS; CRYPTOCOCCUS ANTIGEN SCREENING; DISEASE COURSE; HEALTH CARE COST; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MORTALITY; POPULATION RISK; POST TREATMENT SURVIVAL; PRIORITY JOURNAL; PROGNOSIS; SENSITIVITY AND SPECIFICITY; SOUTH AFRICA; UGANDA;

AIDS-RELATED OPPORTUNISTIC INFECTIONS; ANTIFUNGAL AGENTS; ANTIGENS, FUNGAL; BIOLOGICAL MARKERS; COST-BENEFIT ANALYSIS; HUMANS; MASS SCREENING; MENINGITIS, CRYPTOCOCCAL; MICROBIOLOGICAL TECHNIQUES; SOUTH AFRICA;

EID: 84859773709     PISSN: 15254135     EISSN: 10779450     Source Type: Journal    
DOI: 10.1097/QAI.0b013e31824c837e     Document Type: Article

References (31)

1. Park BJ, Wannemuehler KA, Marston BJ, et al. Estimation of the current global burden of cryptococcal meningitis among persons living with HIV/AIDS. AIDS. 2009;23:525-530.
2. Gordon SB, Walsh AL, Chaponda M, et al. Bacterial meningitis in Malawian adults: pneumococcal disease is common, severe, and seasonal. Clin Infect Dis. 2000;31:53-57. (Pubitemid 32268938)
3. Hakim JG, Gangaidzo IT, Heyderman RS, et al. Impact of HIV infection on meningitis in Harare, Zimbabwe: a prospective study of 406 predominantly adult patients. AIDS. 2000;14:1401-1407. (Pubitemid 30459513)
4. Jarvis JN, Meintjes G, Williams A, et al. Adult meningitis in a setting of high HIV and TB prevalence: findings from 4961 suspected cases. BMC Infect Dis. 2010;10:67.
5. World Health Organization, UNAIDS. Towards Universal Access: Scaling up Priority HIV/AIDS Interventions in the Health Sector. Progress Report 2010. World Health Organization, Geneva, Switzerland. 53. Available at: http://www.who.int/hiv/topics/treatment/data/en/index2.html. Accessed October 1, 2011.
6. Jarvis JN, Lawn SD, Wood R, et al. Cryptococcal antigen screening for patients initiating antiretroviral therapy: time for action. Clin Infect Dis. 2010;51:1463-1465.
7. Lawn SD, Myer L, Harling G, et al. Determinants of mortality and non-death losses from an antiretroviral treatment service in South Africa: implications for program evaluation. Clin Infect Dis. 2006;43:770-776. (Pubitemid 44330743)
8. Trachtenberg JD, Kambugu AD, McKellar M, et al. The medical management of central nervous system infections in Uganda and the potential impact of an algorithm-based approach to improve outcomes. Int J Infect Dis. 2007;11:524-530. (Pubitemid 47626046)
9. Kambugu A, Meya DB, Rhein J, et al. Outcomes of cryptococcal meningitis in Uganda before and after the availability of highly active anti-retroviral therapy. Clin Infect Dis. 2008;46:1694-1701. (Pubitemid 351706766)
10. Boulware DR, Meya DB, Bergemann TL, et al. Clinical features and serum biomarkers in HIV immune reconstitution inflammatory syndrome after cryptococcal meningitis: a prospective cohort study. PLoS Med. 2010;7:e1000384.
11. Bicanic T, Jarvis J, Loyse A, et al. Determinants of acute outcome and long-term survival in HIV-associated cryptococcal meningitis: results from a combined cohort of 523 patients [abstract 892]. Presented at: Conference on Retroviruses and Opportunistic Infections (CROI); March 3, 2011; Boston, MA.
12. Jarvis JN, Lawn SD, Vogt M, et al. Screening for cryptococcal antige-nemia in patients accessing an antiretroviral treatment program in South Africa. Clin Infect Dis. 2009;48:856-862.
13. Jarvis JN, Harrison TS. HIV-associated cryptococcal meningitis. AIDS. 2007;21:2119-2129. (Pubitemid 350287209)
14. French N, Gray K, Watera C, et al. Cryptococcal infection in a cohort of HIV-1-infected Ugandan adults. AIDS. 2002;16:1031-1038. (Pubitemid 34499426)
15. Meya DB, Manabe YC, Castelnuovo B, et al. Cost-effectiveness of serum cryptococcal antigen screening to prevent deaths among HIV-infected persons with a CD4+ cell count, or = 100 cells/microL who start HIV therapy in resource-limited settings. Clin Infect Dis. 2010;51:448-455.
16. Desmet P, Kayembe KD, De Vroey C. The value of cryptococcal serum antigen screening among HIV-positive/AIDS patients in Kinshasa, Zaire. AIDS. 1989;3:77-78. (Pubitemid 19073455)
17. Tassie JM, Pepper L, Fogg C, et al. Systematic screening of cryptococcal antigenemia in HIV-positive adults in Uganda. J Acquir Immune Defic Syndr. 2003;33:411-412. (Pubitemid 36859071)
18. Liechty CA, Solberg P, Were W, et al. Asymptomatic serum cryptococ-cal antigenemia and early mortality during antiretroviral therapy in rural Uganda. Trop Med Int Health. 2007;12:929-935. (Pubitemid 47245826)
19. Pongsai P, Atamasirikul K, Sungkanuparph S. The role of serum cryp-tococcal antigen screening for the early diagnosis of cryptococcosis in HIV-infected patients with different ranges of CD4 cell counts. J Infect. 2010;60:474-477.
20. Worodria W, Massinga-Loembe M, Mazakpwe D, et al. Incidence and predictors of mortality and the effect of tuberculosis immune reconstitu-tion inflammatory syndrome in a cohort of TB/HIV patients commencing antiretroviral therapy. J Acquir Immune Defic Syndr. 2011;58:32-37.
21. Lawn SD, Myer L, Bekker LG, et al. Tuberculosis-associated immune reconstitution disease: incidence, risk factors and impact in an antiretro-viral treatment service in South Africa. AIDS. 2007;21:335-341. (Pubitemid 46175045)
22. Feldmesser M, Harris C, Reichberg S, et al. Serum cryptococcal antigen in patients with AIDS. Clin Infect Dis. 1996;23:827-830. (Pubitemid 26331133)
23. Kendi C, Penner J, Otieno B, et al. Routine cryptococcal screening and treatment in Kenya: outcomes after six months of follow-up [abstract: TUPE150]. Presented at: International AIDS Society; July 17, 2011; Rome, Italy.
24. Lindsley MD, Mekha N, Baggett HC, et al. Evaluation of a newly developed lateral flow immunoassay for the diagnosis of cryptococcosis. Clin Infect Dis. 2011;53:321-325.
25. Jarvis JN, Percival A, Bauman S, et al. Evaluation of a novel point-of-care cryptococcal antigen test on serum, plasma, and urine from patients with HIV-associated cryptococcal meningitis. Clin Infect Dis. 2011;53:1019-1023.
26. Micol R, Lortholary O, Sar B, et al. Prevalence, determinants of positiv-ity, and clinical utility of cryptococcal antigenemia in Cambodian HIV-infected patients. J Acquir Immune Defic Syndr. 2007;45:555-559. (Pubitemid 47294928)
27. Jarvis JN, Meintjes G, Wood R, et al. Testing but not treating: missed opportunities and lost lives in the South African antiretroviral therapy programme. AIDS. 2010;24:1233-1235.
28. Mills EJ, Bakanda C, Birungi J, et al. Life expectancy of persons receiving combination antiretroviral therapy in low-income countries: a cohort analysis from Uganda. Ann Intern Med. 2011;155:209-216.
29. Bicanic T, Brouwer AE, Meintjes G, et al. Relationship of cerebrospinal fluid pressure, fungal burden and outcome in patients with cryptococcal meningitis undergoing serial lumbar punctures. AIDS. 2009;23:701-706.
30. Longley N, Muzoora C, Taseera K, et al. Dose response effect of high-dose fluconazole for HIV-associated cryptococcal meningitis in southwestern Uganda. Clin Infect Dis. 2008;47:1556-1561.
31. WHO. Rapid advice: diagnosis, prevention and management of crypto-coccal disease in HIV-infected adults, adolescents and children. 2011. Available at: www.who.int/hiv/pub/cryptococcal-disease2011. Accessed January 1, 2012.